Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8293492 | 0.91 | LMNA (0.41) | LMNARAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1669840 | 0.84 | LMNA (0.59) | LMNASLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL3485368 | 0.84 | LMNA (0.38) | LMNARAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL23129641 | 0.82 | LMNA (0.57) | LMNASLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL1672623 | 0.82 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1CYP3A4 | |
| SCHEMBL698391 | 0.81 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL4630436 | 0.81 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL18072127 | 0.80 | LMNA (0.47) | LMNASLC1A3SLC1A2SLC1A1CTSK | |
| SCHEMBL3117465 | 0.79 | ALDH1A1 (0.52) | LMNASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL3424857 | 0.79 | LMNA (0.35) | LMNARAB9AMEN1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| US-9926336-B2 | Beta-lactamase inhibitors | VENATORX PHARMACEUTICALS (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9783555-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783555-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-10 | — | — | US | disclosed |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-10 | — | — | US | disclosed |
| US-9637504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| US-20150361107-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | LMNA 542/4885RAB9A 1933/4885SLC1A3 4585/4885 |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | LMNA 2544/4885RAB9A 1299/4885SLC1A3 74/4885 |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | LMNA 902/4885RAB9A 1066/4885SLC1A3 1832/4885 |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | LMNA 2736/4885RAB9A 2417/4885SLC1A3 1058/4885 |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | LMNA 542/4885RAB9A 1933/4885SLC1A3 4585/4885 |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | LMNA 542/4885RAB9A 1933/4885SLC1A3 4585/4885 |
| US-20150361107-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | SI, ALPI, GAA | LMNA 646/4885RAB9A 1272/4885SLC1A3 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.